Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of BAVA-CO would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2000) — listing | $73,214 1.8× | $105,575 1.8× |
| Year 6 (2005) | $50,270 1.6× | $73,505 1.6× |
| Year 11 (2010) | $40,630 1.7× | $59,491 1.7× |
| Year 16 (2015) | $17,166 1.0× | $25,189 1.0× |
| Year 21 (2020) | $9,169 1.0× | $13,432 1.0× |
| Year 26 (2025) | $2,046 1.0× | $3,025 1.0× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Headquarters
Hellerup, Denmark
Popular scenarios with BAVA
For illustration only — not investment advice. Past performance is not indicative of future results.